Honoring The Best of Colorado's Bioscience Industry

Colorado BioScience Association Announces Winners Of Its 2006 Awards Program

23-Aug-2006

The Colorado BioScience Association (CBSA) has released winners of its 2006 Awards Program. Official presentation of the awards occurs Thursday evening, August 24, at the CBSA's annual awards banquet, held in conjunction with the 2006 BioWest conference.

Recipients of the 2006 awards include:

2006 Company of the Year Award -- Myogen, Inc.

Fungi-based meat alternatives to help save Earth’s forests

Green biotechnology needs to be fuelled by green energy

Read news

Myogen is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders. The company has had an outstanding 2006 and is dedicated to the growth of the Colorado bioscience industry. The company was founded 10 years ago based on technology from the University of Colorado, became a public company in 2003 and has a current market capitalization of $1.4 billion.

In the past nine months, Myogen's clinical development efforts were rewarded with positive results from both of its pivotal Phase 3 clinical trials of ambrisentan for the treatment of patients with pulmonary arterial hypertension (PAH). These results will form the foundation of a New Drug Application for ambrisentan that Myogen will submit to the Food and Drug Administration in the fourth quarter of 2006.

In March of this year, Myogen entered into a global collaboration with GlaxoSmithKline (GSK) in the area of PAH. As part of the collaboration, Myogen obtained marketing and distribution rights for Flolan, a marketed drug for the treatment of advanced PAH. Myogen launched commercial operations, including a PAH focused sales force, in the second quarter of 2006.

2006 Rising Star Awards

C5 Medical Werks is a provider of ceramic solutions for medical device industries and their relationship with CoorsTek brings almost a century of experience in ceramic ware to the company. Since the formation in early 2005 the company has grown substantially and is already a multi-million dollar business. The company forecasts a significant growth in revenue and plans to double the number of Colorado based full-time employees in the coming year. C5 Medical Werks is a spin-off of CoorsTek and was founded by J. Brad Coors in 2005. In late 2005, the company located its manufacturing operation in Grand Junction, Colorado.

Taligen Therapeutics is a biotechnology company founded in March 2004 and located at the Fitzsimons Bioscience Park Center. The company develops and commercializes technology from the University of Colorado for the treatment of serious inflammatory disease. Taligen was the recipient of the University's inaugural Proof of Concept (POC) fund in the fall of 2004 and was the first recipient of an investment from the Colorado Venture Capital Authority in 2005. The Company employs technologies to manipulate complement proteins of the immune system to inhibit inflammation and to target inhibitors of inflammation to specific sites of tissue injury. Based on medical need, the competitive landscape and pre-clinical data, Taligen's initial focus is on the major unmet medical need of severe refractory asthma.

https://www.bionity.com/en/news/57266/honoring-the-best-of-colorado-s-bioscience-industry.html